STAT1 and central nervous system cancer: The results showed that IgG, HCK, MHC-II, LCK, STAT1 interferon, B7-CD28, and TNF-related tumor immune responses were significantly enhanced with the increasing risk scores, indicating that the immune microenvironment in high-risk glioma patients regulates response changes (Figure 7C).